All In Biotech

Drug Trial Radar · NCT06012136

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled, Randomized, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Parenterally Administered Suspension of Investigational Capsid Inhibitors in Healthy Adults

Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Aug 24, 2023

Primary completion

Jun 9, 2026

Study completion Jun 9, 2026

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Aug 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to investigate safety and tolerability following single and multiple ascending subcutaneous (SC) and intramuscular (IM) doses of capsid inhibitors in healthy participants. The study will also describe the pharmacokinetics following single and multiple ascending SC and IM doses of capsid inhibitors in healthy participants.

Conditions

  • HIV Infections

Interventions

  • VH4004280Drug

    VH4004280 will be administered.

  • PlaceboDrug

    Placebo will be administered.

  • VH4011499Drug

    VH4011499 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAD: Number of Participants with Adverse Events (AEs) as per SeverityTime frame: Up to Week 52
  2. MAD: Number of Participants with Adverse Events (AEs) as per SeverityTime frame: Up to Week 56
  3. SAD: Absolute Values of Liver Chemistry Parameters: Total Bilirubin and Direct Bilirubin (micromoles per liter [umol/L])Time frame: Up to Week 52
  4. MAD: Absolute Values of Liver Chemistry Parameters: Total Bilirubin and Direct Bilirubin (micromoles per liter [umol/L])Time frame: Up to Week 56
  5. SAD: Change from Baseline in Liver Chemistry Parameters: Total Bilirubin and Direct Bilirubin (umol/L)Time frame: Baseline (Prior to Day 1) and up to Week 52
  6. MAD: Change from Baseline in Liver Chemistry Parameters: Total Bilirubin and Direct Bilirubin (umol/L)Time frame: Baseline (Prior to Day 1) and up to Week 56
  7. SAD: Number of Participants with Maximum Toxicity Grade Change from Baseline in Liver Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT)Time frame: Up to Week 52
  8. MAD: Number of Participants with Maximum Toxicity Grade Change from Baseline in Liver Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT)Time frame: Up to Week 56
  9. SAD: Absolute Values of Liver Chemistry Parameters: Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) (International Units per liter)Time frame: Up to Week 52
  10. MAD: Absolute Values of Liver Chemistry Parameters: Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) (International Units per liter)Time frame: Up to Week 56
  11. SAD: Change from Baseline in Liver Chemistry Parameters: Alkaline Phosphatase, AST, and ALT (International Units per liter)Time frame: Baseline (Prior to Day 1) and up to Week 52
  12. MAD: Change from Baseline in Liver Chemistry Parameters: Alkaline Phosphatase, AST, and ALT (International Units per liter)Time frame: Baseline (Prior to Day 1) and up to Week 56
  13. SAD: Number of Participants with Injection Site Reactions (ISR) AE by Grade Using the DAIDS Grading ScaleTime frame: Up to Week 52
  14. MAD: Number of Participants with Injection Site Reactions (ISR) AE by Grade Using the DAIDS Grading ScaleTime frame: Up to Week 56
  15. SAD: Duration of ISR (Days) AETime frame: Up to Week 52
  16. MAD: Duration of ISR (Days) AETime frame: Up to Week 56
  17. Area Under the Plasma-concentration Time curve from Time Zero to Infinity (AUC0-inf) of VH4004280Time frame: Up to Week 52
  18. Area Under the Plasma-concentration Time curve from Time Zero to Infinity (AUC0-inf) of VH4011499Time frame: Up to Week 56
  19. Maximum Observed Plasma Concentration (Cmax) of VH4004280Time frame: Up to Week 52
  20. Maximum Observed Plasma Concentration (Cmax) of VH4011499Time frame: Up to Week 56
  21. Time of Maximum Observed Plasma Concentration (tmax) of VH4004280Time frame: Up to Week 52
  22. Time of Maximum Observed Plasma Concentration (tmax) of VH4011499Time frame: Up to Week 56
  23. Apparent Terminal Half-life (t1/2) of VH4004280Time frame: Up to Week 52
  24. Apparent Terminal Half-life (t1/2) of VH4011499Time frame: Up to Week 56

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.